

# Synthesis of $^{125}\text{I}$ Labeled Estradiol-17 $\beta$ -Hemisuccinate and Its Binding Study to Estrogen Receptors Using Scintillation Proximity Assay Method

Y. Susilo<sup>1,2\*</sup>, G. Mondrida<sup>2</sup>, S. Setiyowati<sup>2</sup>, Sutari<sup>2</sup>, Triningsih<sup>2</sup>, W. Lestari<sup>2</sup>, P. Widayati<sup>2</sup>, C.N. Ardiyatno<sup>2</sup>, A. Ariyanto<sup>2</sup>, S. Darwati<sup>2</sup>, L.B.S. Kardono<sup>3</sup>, A. Yanuar<sup>1</sup>

<sup>1</sup>Faculty of Pharmacy, University of Indonesia  
Depok, 16424, Indonesia

<sup>2</sup>Center for Radioisotopes and Radiopharmaceuticals, National Nuclear Energy Agency  
Puspptek Area, Serpong, 15314, Indonesia

<sup>3</sup>Program for Food Health and Medical Sciences, International Center for Interdisciplinary and Advanced Research  
Indonesian Institute of Sciences, Jl. Gatot Subroto 10, Jakarta 12710, Indonesia

## ARTICLE INFO

### Article history:

Received 04 December 2012

Received in revised form 19 December 2012

Accepted 21 December 2012

### Keywords:

Indirect labeling

Estrogen receptor

Estradiol

Scintillation proximity assay

Binding affinity

MCF7

## ABSTRACT

Research was carried out to obtain a selective ligand which strongly bind to estrogen receptors through determination of binding affinity of estradiol-17 $\beta$ -hemisuccinate. Selectivity of these compounds for estrogen receptor was studied using Scintillation Proximity Assay (SPA) method. Primary reagents required in the SPA method including radioligand and receptor, the former was obtained by labeling of estradiol-17 $\beta$ -hemisuccinate with  $^{125}\text{I}$ , while MCF7 was used as the receptor. The labeling process was performed by indirect method via two-stage reaction. In this procedure, first step was activation of estradiol-17 $\beta$ -hemisuccinate using isobutylchloroformate and tributylamine as a catalyst, while labeling of histamine with  $^{125}\text{I}$  was carried out using chloramin-T method to produce  $^{125}\text{I}$ -histamine. The second stage was conjugation of activated estradiol-17 $\beta$ -hemisuccinate with  $^{125}\text{I}$ -histamine. The product of estradiol-17 $\beta$ -hemisuccinate labeled  $^{125}\text{I}$  was extracted using toluene. Furtherly, the organic layer was purified by TLC system. Characterization of estradiol-17 $\beta$ -hemisuccinate labeled  $^{125}\text{I}$  from this solvent extraction was carried out by determining its radiochemical purity and the result was obtained using paper electrophoresis and TLC were 79.8% and 84.4% respectively. Radiochemical purity could be increased when purification step was repeated using TLC system, the result showed up to 97.8%. Determination of binding affinity by the SPA method was carried out using MCF7 cell lines which express estrogen receptors showed the value of Kd at  $7.192 \times 10^{-3}$  nM and maximum binding at 336.1 nM. This low value of Kd indicated that binding affinity of estradiol-17 $\beta$ -hemisuccinate was high or strongly binds to estrogen receptor.

© 2012 Atom Indonesia. All rights reserved

## INTRODUCTION

Breast cancer is a malignant condition of the cells contained in the breast. Breast cancer is one of the leading causes of cancer death among women and more than one million cases a year are found around the world [1]. Molecular mechanisms of breast cancer begin with a mutation in the normal gene. Mutation occur are usually point mutations, among others, could caused to rearrangement or deletion [1]. Two-thirds of breast cancers express estrogen receptor (ER). The ER status is important as a prognostic indicator in breast cancer. Women

with estrogen receptor positive breast tumors have a better prognosis than women with estrogen receptor negative tumors in the treatment with the antiestrogen [2].

Estrogen receptor is one of the intracellular receptor (nuclear receptor) that mediates the action of 17 $\beta$ -estradiol (estrogen) hormone in the body. The presence of estrogen is able to initiate growth, proliferation and metastasis of various types of cancers (breast, ovarian, colorectal, prostate, and endometrial) [3].

If an estrogen receptor (ER) binds to the ligand, there will be a change in receptor conformation that allows binding with coactivator. Estrogen receptor complex then binds with estrogen receptor element (ERE). After binding with ERE,

\* Corresponding author.

E-mail address: veronika@batan.go.id

the complex binds to a protein coactivator and activates transcription factors. Activation of gene transcription was going to produce mRNA that directs the synthesis of specific proteins, which then affects cell function, depending on their target cells [4].

Ligand that would bind to estrogen receptors was then compete with estrogen for binding to its receptor and was called Selective Estrogen Receptor Modulators (SERMs). This selectivity may be achieved due to the estrogen receptor in different tissues vary in their chemical structure that allows a group of SERMs drugs to selectively interact on estrogen receptors in certain tissues [4].

To obtain a selective ligand which strongly bind to estrogen receptor, study is needed to determine the selectivity of compound to be used as a ligand. In this study, analog of the ligand that will bind to estrogen receptors of the steroid compound will be used, which is estradiol-17 $\beta$ -hemisuccinate.

The presence of hydroxyl groups on the C3 aromatic ring of estradiol-17 $\beta$ -hemisuccinate indicates an ability to bind to estrogen receptors. This is reasonable because one of pharmacophore was required to bind to the estrogen receptor is the presence of an aromatic ring substituted with a hydroxyl group [5]. The main frame of estradiol-17 $\beta$ -hemisuccinate contributed an estimated affinity for estrogen receptor  $\alpha$  through hydrophobic interactions with binding of the ligand and estrogen receptor  $\alpha$  [6].

The binding affinity of estradiol-17 $\beta$ -hemisuccinate to the estrogen receptor in MCF7 cell lines was studied using scintillation proximity assay (SPA) method. The SPA is a technique which determine binding of antibodies or receptor molecules to a bead which emit light from the energy of labeled radioactive ligand. This occurrence triggers the release of light from the beads and therefore can be detected by detector [7]. The SPA method does not require any separation or washing step because of its homogeneous form [8], thus the method is easy to be applied for drug screening [9]. The factors affecting the determination by the SPA technique are the use of solvent (assay buffer), the type of ligand or compound to be determined and the type of bead [10].


In this study determination of binding affinity of estradiol-17 $\beta$ -hemisuccinate to the estrogen receptor was performed by in vitro test with SPA method using estradiol-17 $\beta$ -hemisuccinate labeled  $^{125}\text{I}$ . The aim of this research is to find an optimum condition for preparation and purification of  $^{125}\text{I}$  labeled estradiol-17 $\beta$ -hemisuccinate using an indirect method, especially to obtain the value of

dissociation constant (Kd) and maximum binding (Bmax) of binding affinity of estradiol-17 $\beta$ -hemisuccinate labeled  $^{125}\text{I}$ . The previous study related to this research (reference no 15) using radioligand binding assay method. In this study using SPA method, is expected to obtain a lower value of Kd.


## EXPERIMENTAL METHOD

### Indirect Labeling of Estradiol-17 $\beta$ -hemisuccinate


The labeling process of estradiol-17 $\beta$ -hemisuccinate was performed in similar manner to procedure reported in Refs [11-14]. This process involved three stages of reactions. It was began by activating the estradiol-17 $\beta$ -hemisuccinate with isobutylchloroformate using tributylamine as catalyst to form an active compound of estradiol-17 $\beta$ -hemisuccinate-isobutylchloroformate (Fig. 1). The second stage was preparation of histamine labeled with  $^{125}\text{I}$  using chloramin-T method (Fig. 2). The final stage was the conjugation of histamine labeled  $^{125}\text{I}$  to the activated estradiol-17 $\beta$ -hemisuccinate-isobutylchloroformate (Fig. 3). The obtained  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine was then purified and tested using labelling efficiency and radiochemical purity parameters.



**Fig. 1.** Activation of estradiol-17 $\beta$ -hemisuccinate with isobutylchloroformate using tributylamine as catalyst.



**Fig. 2.** Labeling histamine with  $^{125}\text{I}$  using chloramin-T method.



**Fig. 3.** Conjugation of  $^{125}\text{I}$ -histamine to the activated estradiol-17 $\beta$ -hemisuccinate

### Scintillation Proximity Assay (SPA)

#### Assay protocol with varying the amount and type of SPA bead

In a Laminar Air Flow, a 100  $\mu\text{L}$  of sterile phosphate buffer saline containing MCF7 cells was added to a plate of 96 well. For well of non specific binding, a 25  $\mu\text{L}$  of unlabeled estradiol-17 $\beta$ -hemisuccinate was placed in the well, while for total binding the well containing a 25  $\mu\text{L}$  phosphate buffer saline. Then a 100  $\mu\text{L}$  of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine in assay buffer and 50  $\mu\text{L}$  of SPA beads suspension were added to each well. The plate was sealed and incubated for 1 h at 25 $^{\circ}\text{C}$ , with shaking. Final assay concentrations were : MCF7 cell lines of 500,000/well, 0.08 nM unlabeled estradiol-17 $\beta$ -hemisuccinate, 400 nM  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine, SPA beads ( 12.5 to 250  $\mu\text{g}/\mu\text{L}$ ). Varying types of beads were used including YSi-WGA SPA, YSi-antirabbit SPA dan PVT-antirabbit SPA beads. The plate was counted using Liquid Scintillation Counter (LSC) at 1 min per well. Results from this experiment can identify the proper type of SPA bead to be used in future experiments.


#### Assay protocol for binding study of $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine [15]

To each well, a 100  $\mu\text{L}$  of sterile phosphate buffer saline containing MCF7 cells was added. A 25  $\mu\text{L}$  of unlabeled estradiol-17 $\beta$ -hemisuccinate was placed in the well for non specific binding. For total binding the well, a 25  $\mu\text{L}$  phosphate buffer saline was added. Varying concentration of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine as a tracer was diluted in assay buffer, then a 100  $\mu\text{L}$  of

tracer and 50  $\mu\text{L}$  of SPA beads suspension were added to each well. The plate was sealed and incubated for 1 h at 25 $^{\circ}\text{C}$ , with shaking. Final assay concentrations : MCF7 cell lines of 500,000/well, 0.08 nM unlabeled estradiol-17 $\beta$ -hemisuccinate, concentration of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine (10 nM to 400 nM), SPA beads (25  $\mu\text{g}/\mu\text{L}$ ). The plate was counted using LSC at 1 min per well. Results from this experiment were used to calculate the value of  $K_d$  and maximum binding ( $B_{\text{max}}$ ).


### RESULTS AND DISCUSSION

The labeling of estradiol-17 $\beta$ -hemisuccinate with  $^{125}\text{I}$  was carried out using indirect method [11-14]. Evaluations of labeling and radiochemical purity were monitored using paper electrophoresis and TLC. Prior to labeling process, a radiochromatogram of  $\text{Na-}^{125}\text{I}$  was prepared and showed in Fig. 4 for paper electrophoresis and TLC. Whatman paper No. 1 was used as stationary phase and 0,025 M phosphate buffer pH 7,4 was used as mobile phase in the electrophoresis method. While for TLC, silica 60F<sub>254</sub> was used as the stationary phase and the mixture of chloroform : ethanol (9 : 1) as mobile phase. The radiochromatogram was used as a reference in identifying the result of labeling process ( $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine). The radiochromatogram of  $\text{Na-}^{125}\text{I}$  (Fig. 4) showed the radiochemical purity at more than 97%, which was good enough for this research [13].




**Fig. 4.** Radiochromatogram of  $\text{Na-}^{125}\text{I}$  using paper electrophoresis (a) and using TLC (b).

The labeling process was performed by indirect method via two-stage reaction. First activation of estradiol-17 $\beta$ -hemisuccinate using isobutylchloroformate and tributylamine as a catalyst, and labeling of histamine was carried out by  $^{125}\text{I}$  using chloramin-T method. The second stage was conjugation of activated estradiol-17 $\beta$ -hemisuccinate with  $^{125}\text{I}$ -histamine. The estradiol-17 $\beta$ -hemisuccinate labeled  $^{125}\text{I}$  was extracted using toluene and organic phase was purified by TLC system. The radiochemical purity of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine was obtained at 79.8% using paper electrophoresis while using TLC was 84.4% as shown in Fig. 5.




**Fig. 5.** Radiochromatogram of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine using paper electrophoresis (a), and using TLC (b).

It can be seen from Fig. 5, that radiochemical purity of the purified  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine was still low. Therefore further purification was a necessary. Further purification was carried out by a semi-preparative TLC glass plate of silica gel 60 F<sub>254</sub> as the stationary phase and a mixture of benzene : ethanol : acetic acid (75 : 24 : 1) as the mobile phase. Radiochromatogram of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine purified with TLC system can be seen in Fig. 6.



**Fig. 6.** Radiochromatogram of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine using TLC glass plate.

Figure 6 showed an increasing purity of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine. Increased purification yield of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine reached 89.9%. Radiochemical purity of purified  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine was then monitored by TLC, using silica 60 F<sub>254</sub> as stationary phase and a mixture of chloroform : ethanol (9 : 1) as a mobile phase. Radiochromatogram for radiochemical purity of purified  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine was obtained at 97.8% as shown in Fig. 7.



**Fig. 7.** Radiochromatogram of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine using TLC.

Purified  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine with high radiochemical purity was then used to observe its binding to estrogen receptors. The estrogen receptors used in this study was breast cancer cells (MCF7 cell lines) that express estrogen receptor  $\alpha$ . The binding study performed after optimization on the amount and type of SPA beads. Various types of beads were used including YSI-WGA SPA, YSI-antirabbit SPA and PVT-antirabbit SPA. At varying amount of SPA beads (12.5  $\mu\text{g}/\text{mL}$  to 250  $\mu\text{g}/\text{mL}$ ). Figure 8a. showed optimum beads was YSI-WGA SPA beads. The results showed that the YSI-WGA SPA beads with concentration of 25  $\mu\text{g}/\text{mL}$  gave total binding (TB) higher than the value of non specific binding

(NSB). For other types of beads (YSI-antirabbit SPA and PVT-antirabbit SPA) gave low values of NSB and TB.

After obtaining the type and amount of the optimum of beads, assay protocol was performed to obtained value of the dissociation constant ( $K_d$ ) and maximum binding values ( $B_{max}$ ). The data from assay protocol was radioactivity of NSB and TB. The data were then calculated to obtain the concentration of NSB and TB, then Rosenthal plot curve was made to get linear regression equation. As shown in Fig. 8b, linear regression equation following formula  $y = -ax + b$ ,  $y = -139.05x + 336.1$ . The regression equation gave the value of  $K_d = - (1/\text{slope}) = - (1/-139,05) = 7.192 \times 10^{-3}$  nM and maximum binding =  $B_{max} = \text{intercept} = 336.1$  nM. The values of  $K_d$  was requirements for  $K_d$  values of estradiol are based on literature at  $< 0.003 - 0.87$  nM [16]. Binding affinity of estradiol-17 $\beta$ -hemisuccinate represented by the value of  $K_d$  at  $7.192 \times 10^{-3}$  nM. This low value of  $K_d$  indicated that binding affinity of estradiol-17 $\beta$ -hemisuccinate was high or strongly bind to estrogen receptor. When compared with literature written by Neto et al, values of  $K_d$  was obtained at 6.14 nM. The difference in affinity is probably related to the ligand lipophilicity [17].

## CONCLUSION

Preparations of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine with indirect labelling method has been carried out. Two stages of purification, solvent extraction and TLC system, were managed to obtain radiochemical purity of  $^{125}\text{I}$ -estradiol-17 $\beta$ -hemisuccinate-iodohistamine at more than 90%. Purification stage yielded at 89,9% and the radiochemical purity at 97,8% was obtained. Determination of binding affinity by the SPA method using MCF7 cell lines which express estrogen receptors, represented by the value of  $K_d$  at  $7.192 \times 10^{-3}$  nM and maximum binding at 336.1 nM. This low value of  $K_d$  indicated that binding affinity of estradiol-17 $\beta$ -hemisuccinate was high or strongly bind to estrogen receptor.

## ACKNOWLEDGEMENTS

The authors are grateful to Dr. Abdul Mutalib, Ex-Head, Centre for Radioisotopes and Radiopharmaceuticals, Radioisotope Division counterparts for their keen interest and valuable support during the work. The authors are thankful to Gadjah Mada University for supplying us with MCF7 cell lines.

## REFERENCES

1. C.E. Brothers, J. Quindry, K. Brittingham, L. Panton, J. Thomson, S. Appakodu, K. Breuel, R. Byrd, J. Douglas, C. Earnest, C. Mitchell, M. Olson, T. Roy and C. Yarlagadda, Arch. Intern. Med. **160** (2000) 3093.
2. L. Vollenweider-Zerargui, L. Barrelet, Y. Wong, T. Lemarchand-Beraud and F. Gomez, The predictive value of estrogen and progesterone receptors concentrations on the clinical behavior of breast cancer in women, Clinical correlation on 547 patients, Cancer **57** (1986) 1171.
3. Y. Jacquot and G. Leclercq, *The Ligand Binding Domain of the Human Estrogen Receptor Alpha: Mapping and Functions*, in: Estrogens: Production, Functions and Applications, James R. Bartos (Ed.), Nova Science Publishers, Inc. (2009) 231.
4. I. Zullies, Introduction to Molecular Pharmacology, Gadjah Mada University Press, (2006) 103.
5. W.L. Duax, J.F. Griffin, C.M. Weeks and K.S. Korach, Environ. Health Persp. **61** (1985) 111.




Fig. 8. Optimization of the type and amount of SPA bead (a), and Rosenthal Plot curve (b)

6. G.M. Anstead, K.E. Carlson and J.A. Katzenellenbogen, The Estradiol Pharmacophore: Ligand Structure-Estrogen Receptor Binding Affinity Relationships and A Model for the Receptor Binding Site, *Steroids*, 62 (1997) 268.
7. J. Osborn, A review of Radioactive and Non-Radioactive-based techniques used in life science applications-Part II: High-throughput screening, Amersham Pharmacia Biotech UK Ltd., Amersham Place, Little Chalfont, Buckinghamshire, UK (2001) 6.
8. J.R. Cook, R. Graves, J. Molly, P. Jones, J.A. Berry and K.T. Hughes, Scintillation Proximity Assay (SPA) Receptor Binding Assays, *Handbook of Assay Development in Drug Discovery*, CRC Press Taylor & Francis Group, USA (2006) 141.
9. P.M. Jones, Scintillation Proximity Assay for Drug Metabolism and Pharmacokinetic applications, *Life Science News* 13, Amersham Bioscience (2003).
10. E. Lilly, The National Institutes of Health Chemical Genomics Center, *Receptor Binding Assay* (2008) 18.
11. J.I. Thorell and B.G. Johansson, *Biochem. Biophys. Acta* (1971) 251, 363, 369
12. B. Green, *Steroid Hormones : A Practical Approach*, R.E lake Departement of Biochemistry, University of Glasgow, Glasgow G12 8QQ, UK (1985).
13. L. Brian, L. Radiolabelling Procedures for Radioimmunoassay, *Immunoassay A Practical Guide*, Taylor & Francis e-Library (2005) 65.
14. K.M. Sallam and N.L. Mehany, *J. Radioanal. Nucl. Chem.* **281** (2009) 329.
15. C. Neto, M.C. Oliviera, L. Gano, F. Marques, I. Santos, G.R. Morais, Y. Takumi, T. Thiemann, F. Botelho and C.F. Oliviera, *Appl. Radiat. Isot.* **67** (2009) 301.
16. S. Eiler, M. Gangloff, S. Duclaud, D. Moras and M. Ruff, *Protein Expression Purif.* **22** (2001) 165.
17. M. Ruff, M. Gangloff, J.M. Wurzt and D. Moras, *Breast Cancer Res.* **2** (2000) 353.